Navigation Links
FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease
Date:7/1/2011

SILVER SPRING, Md., July 1, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Arcapta Neohaler (indacaterol inhalation powder) for the long term, once-daily maintenance bronchodilator treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

COPD is a serious lung disease that makes breathing difficult. Symptoms can include breathlessness, chronic cough and excessive phlegm. Cigarette smoking is the leading cause of COPD, and is the fourth leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

Arcapta Neohaler is a new molecular entity in the beta2-adrenergic agonist class that helps muscles around the airways of the lungs stay relaxed to prevent symptoms of COPD, such as wheezing and breathlessness. Arcapta Neohaler is not intended to treat asthma or sudden, severe symptoms of COPD.

"The approval of new long-term drugs for COPD that relieve breathing difficulty by opening airways provides another treatment option for the millions of people," said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research.

The safety and efficacy of Arcapta Neohaler was demonstrated in six confirmatory clinical trials that included 5,474 patients ages 40 and older with a clinical diagnosis of COPD. Those treated had a smoking history of at least one pack a day for 10 years and exhibited moderate-to-severe decreases in lung function.

Arcapta Neohaler carries a boxed warning that long-acting beta2 adrenergic agonists (LABA) increase the risk of asthma-related death. All LABA, including Arcapta Neohaler, should not be used in patients with asthma, unless used with a long-term asthma control medication.

The FDA approved Arcapta Neohaler with a medication guide that includes instructions for use and information about the potential risks of taking the drug. The most common side effects reported by those using Arcapta Neohaler include runny nose, cough, sore throat, headache and nausea.  

Arcapta Neohaler is marketed by Novartis Pharmaceuticals Corp. of East Hanover, N.J.

For more information:

National Heart, Lung, and Blood Institute: Chronic Obstructive Pulmonary Disease
http://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_WhatIs.html

Approved Drugs: Questions and Answers
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

Media Inquiries: Morgan Liscinsky, 301-796-0397, morgan.liscinsky@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
2. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
3. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
4. FDA Approves Nulojix for Kidney Transplant Patients
5. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
6. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
7. FDA Approves Redesigned Labels for Some Merck Drugs
8. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
9. FDA Approves Marketing of RMS Subcutaneous Needle Sets
10. FDA Approves Injectable Gel to Treat Fecal Incontinence
11. FDA approves Incivek for hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... WILLIAMSTON, Mich. , July 13, 2017  Centurion Medical Products, ... offers its DisImpactor ® fecal impaction removal device for hospice ... ... Patient pain management ... DisImpactor for Hospice can help alleviate patient pain while preventing unneeded ...
(Date:7/12/2017)... July 12, 2017 CarpalAID is a revolutionary new product ... surgery. Carpal tunnel syndrome affects more than 8 million ... the rate of men. The common methods of treating CTS are ... uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn on ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... Theater of Witness , was awarded a $300,000 grant from The Pew ... fosters empathy, comfort with ambiguity and the recognition of one’s own limits among ...
(Date:7/21/2017)... ... 2017 , ... The Margarian Law Firm has filed a class action ... for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ginger ... alleges Canada Dry Ginger Ale claims on its bottle that it is made from ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... 4th-year medical students improve their chances of acceptance to a residency in a ... who have earned degrees outside the U.S. , According to data released by ...
(Date:7/21/2017)... CA (PRWEB) , ... July 21, 2017 , ... West ... “Tu” Tuantu Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West ... 27 years of experience in dermatology, skin cancer , and more. She graduated ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians ... on the rise, say researchers presenting their work at the American Orthopaedic ... “The combination of evaluating the patterns of change in concussion symptom presentation, diagnostic ...
Breaking Medicine News(10 mins):